Combined features based on MT1-MMP expression, CD11b + immunocytes density and LNR predict clinical outcomes of gastric cancer

Chun-Wei Peng1,2, Lin-Wei Wang1,2, Min Fang1,2, Gui-Fang Yang3, Yan Li1,2* and Dai-Wen Pang4

Abstract

Background: Given the complexity of tumor microenvironment, no single marker from cancer cells could adequately predict the clinical outcomes of gastric cancer (GC). The objective of this study was to evaluate the prognostic role of combined features including conventional pathology, proteinase and immune data in GC.

Methods: In addition to pathological studies, immunohistochemistry was used to assess membrane-type 1 matrix metalloproteinase (MT1-MMP) expression and CD11b + immunocytes density in three independent GC tissue microarrays containing 184 GC tissues. Separate and combined features were evaluated for their impact on overall survival (OS).

Results: We found that traditional factors including tumor size, histological grade, lymph node status, serosa invasion and TNM stage were associated with OS ($P < 0.05$ for all). Moreover, statistically significant differences in OS were found among lymph node ratio (LNR) subgroups ($P < 0.001$), MT1-MMP subgroups ($P = 0.015$), and CD11b + immunocytes density subgroups ($P = 0.031$). Most importantly, combined feature (MT1-MMP positive, low CD11b + immunocytes density and high LNR) was found by multivariate analysis to be an independent prognostic factors for OS after excluding other confounding factors (HR = 3.818 [95%CI: 2.223-6.557], $P < 0.001$). In addition, this combined feature had better performance in predicting clinical outcomes after surgery long before recurrence had occurred (Area under the curve: 0.689 [95%CI: 0.609-0.768], $P < 0.001$).

Conclusions: These findings indicate that better information on GC prognosis could be obtained from combined clinico-pathological factors, tumor cells and the tumor microenvironment.

Keywords: Gastric cancer, Prognosis, Tumor microenvironment, Lymph node ratio

Background

Gastric cancer (GC) is the fourth most common cancer and the third cause of cancer death worldwide [1]. Considerable progress has been made in the early diagnosis of cancer, but there has not been a comparable advance in the accuracy of clinical outcome prediction [2]. Only the TNM classification of the International Union Against Cancer (UICC) or American Joint Committee on Cancer (AJCC) is used on a routine basis, which is the most important instrument to guide treatment strategy for GC patients [3]. However, GCs have significant heterogeneity in their biologic behaviors, and tumors of the same clinical stage often show differences in clinical course and treatment response [4]. Thus, identification of factors affecting invasion and metastasis, and establishment of biomarkers panels to predict malignant potential and to identify different risk groups are of a paramount importance.

Despite years of research and hundreds of reports on tumor markers in GC, the number of clinically useful markers is pitifully small [5]. Recently, a new prognostic tool of lymph node ratio (LNR), defined as the number of MLN divided by the number of lymph nodes retrieved, was proposed. It can improve the prognosis accuracy and reduce the stage migration when compared...
with the UICC (2002, 6th edition) staging system \[6,7\]. LNR has been considered as one of the best clinicopathologic variables for prediction of prognosis of gastric cancer after curative surgery in retrospective studies \[8\], which is the success in the optimization of traditional clinical markers. However, the discovery of other so-called promising markers in laboratory translates rather slowly into clinical applicability. One reason for this is the fact that cancer development and progression is determined by the co-evolution between tumor cells and tumor microenvironment rather than a single mutation \[9\]. Such co-evolution has been reported by many studies, all of which indicate that interactions between tumor cells and tumor stromal create a unique and dynamic microenvironment to affect tumor progression \[10\]. Therefore, screening new molecular factors from the complex tumor microenvironment (cellular and stromal components) represents another essential approach to identify prognostic factors.

MT1-MMP is known as a membrane-type matrix metalloproteinase, and MT1-MMP–mediated extracellular matrix (ECM) degradation by tumor cells or stromal cells is essential for cancer invasion through basement membranes and stromal interstitial matrix \[11\]. Although MT1-MMP has shown prognostic significance in several human cancers, such as breast cancer, pancreatic cancer and colorectal cancer \[12,13\], little is known about the accurate significance of MT1-MMP in GC patients. Major contributors to the tumor microenvironment are inflammation and inflammatory mediators \[9\]. It has been proposed that the immune contexture may influence the clinical outcome of the cancer patients, and the immune score would be an important predictor comparable to TNM classification \[14\]. CD11b is expressed by a specific subset of myeloid cells, including CD34+ progenitors, monocytes, granulocytes, NK cells and activated T cells, accounting for the innate immunity \[15,16\]. The role of tumor immunogenicity and immunotherapies are being discussed \[17\]. Extending our knowledge of the complex role of immune cells in GC could ultimately pave the way for the long-awaited successful development of therapeutics.

Based on this understanding, we investigated prognostic role of cellular protease marker MT1-MMP and microenvironment immune marker CD11b + immunocytes in GC. Special attention was paid to the prognostic value of the combined features of MT1-MMP, CD11b + immunocytes density and LNR.

**Methods**

**Patients and follow-up**

The records of GC patients who underwent surgery with a curative intent at the Department of Oncology, Zhongnan Hospital of Wuhan University (Wuhan, China) between December 2002 and February 2011 were reviewed. Major demographic and clinicopathological characteristics were available. No patients received neoadjuvant chemotherapy before surgery. TNM stage was determined according to the 7th edition UICC/AJCC TNM system \[18\]. By the most recent follow-up on May 31, 2012, the median follow-up was 59.5 (range: 16.8-102.3) months. A total of 108 (58.7%) patients died. Overall survival (OS) was defined as the interval from the date of surgery to GC-related death. Any recurrence in abdomino-pelvic cavity was defined as local-regional recurrence; and recurrence via blood flow was defined as distant metastasis, such as liver metastasis and lung metastasis. Written informed consent was obtained from the patients and the study protocol was approved by the ethics committee of Zhongnan Hospital of Wuhan University. The study was undertaken according to the ethical standards of the World Medical Association Declaration of Helsinki.

**Gastric cancer specimens and tissue microarrays**

All hematoxylin and eosin (HE)-stained slides were examined by independent reviewers who were not aware of the clinical characteristics or clinical outcomes. Three tissue microarrays (TMAs) were constructed. Briefly, two cores were taken from each representative tumor tissue (1.5 mm in diameter for each core). Then, three TMAs sections with 184 tumor tissues were constructed (in collaboration with Shanghai Biochip Company Ltd., Shanghai, China).

**Immunohistochemistry and evaluation of immunohistochemical findings**

The primary antibodies for MT1-MMP (sc101451, Santa Cruz, USA, dilution 1/100), CD11b + (ab52478, Abcam, UK, dilution 1/100), the corresponding horseradish peroxidase (HRP) conjugated secondary antibody (ab97265, ab97200, Abcam, UK, dilution 1/300), and diaminobenidine (DAKO, Denmark) were obtained and validated for labeling.

The immunohistochemistry protocols were described previously \[19\]. In short, three TMAs sections were deparaffinised with xylene then rehydrated through three changes of alcohol. Endogenous peroxidase activity was blocked by 0.3% hydrogen peroxide for 10 min. Antigen retrieval was performed by microwave treatment in 0.01 M Tris-EDTA buffer (pH 9.0) for 20 min. Slides were incubated for 1 h with the primary antibodies for MT1-MMP (sc101451, Santa Cruz, USA, dilution 1/100), CD11b + (ab52478, Abcam, UK, dilution 1/100). After washing with Tris-buffered saline (TBS, pH 7.4), sections were incubated with b the corresponding horseradish peroxidase (HRP) conjugated secondary antibody (ab97265, ab97200, Abcam, UK, dilution 1/300) for a further 50 min. Antigen–antibody reaction was visualised with 3,30-diaminobenidine (DAKO, Denmark). After counterstaining with haematoxylin, sections were dehydrated through ascending alcohols
The slides were examined under Olympus BX51 fluorescence microscope equipped with an Olympus DP72 camera (Olympus Optical Co., Ltd., Tokyo, Japan). Panorama of each labeled core was obtained based on 4 photographs under low-power magnification (×100) with high resolution by DP-BSW software (Olympus Optical Co., Ltd., Tokyo, Japan). Identical settings were used for every photograph, so as to minimize the selection bias. The MT1-MMP expression and CD11b+ immunocytes density were digitally evaluated by Image-Pro Plus v6.2 software (Media Cybernetics Inc, Bethesda, MD). To keep results reliable and comparable, a uniform setting for all the slides was applied for the reading of each antibody staining. Integrated optical density (IOD) of all the positive staining of MT1-MMP in each photograph was measured, and its ratio to total area of each photograph was calculated as MT1-MMP expression. CD11b+ immunocytes density was recorded as the number of positive cells per tissue surface unit in square millimeters. Cut points for MT1-MMP density was explored by the best cut-off approach by log-rank test [20]. And the 25th percentile value was defined as the cut-off point to determine the MT1-MMP negative and positive expression subgroups in this study. For the CD11b+ immunocytes density, the cut-off point for the definition of subgroups (low and high CD11b+ immunocytes density) was the median value.

### Table 1 Patients’ demographics and clinico-pathological characteristics (Continued)

#### Clinical status at the end of the follow up
- Live and without recurrence: 72 (39.1)
- Dead or alive with recurrence: 112 (60.9)
- MT1-MMP expression:
  - Negative: 46 (33.3)
  - Positive: 138 (66.7)
- CD11b+ immunocytes (cells/mm²):
  - Median (range): 257 (4-2101)

**Notes:**
- Others included adenosquamous carcinoma in 3 (1.62%) cases, untypical carcinoid in 1 (0.54%) case, and neuroendocrine carcinoma in 1 (0.54%) case.
- 60 recurrent cases were evaluated.

### Table 1 Patients’ demographics and clinico-pathological characteristics

| Items                                           | Value        |
|-------------------------------------------------|--------------|
| Age (M ± SD, yrs)                               | 57.9 ± 12.9  |
| Gender                                          |              |
| Male (%)                                        | 132 (71.7)   |
| Female (%)                                      | 52 (28.3)    |
| Tumor location                                  |              |
| Distal stomach (%)                              | 98 (53.3)    |
| Non-distal stomach (%)                         | 86 (46.7)    |
| Pathological types                              |              |
| Adenocarcinoma                                  |              |
| Histological grade 1/2                         | 55 (29.9)    |
| Well/Moderately differentiated adenocarcinoma (%)| 55 (29.9)    |
| Histological grade 3/4                         | 124 (67.4)   |
| Low/Undifferentiated adenocarcinoma (%)         | 102 (55.4)   |
| Mucinous adenocarcinoma/ signet-ring cell carcinoma | 22 (12.0)    |
| Others a (%)                                    | 5 (2.7)      |
| Serosa invasion                                 |              |
| No (T0, T1, T2) (%)                            | 27 (14.7)    |
| Yes (T3, T4) (%)                                | 157 (85.3)   |
| Lymph node metastasis                           |              |
| No (N0) (%)                                     | 53 (28.8)    |
| Yes (N1, N2, N3) (%)                            | 131 (71.2)   |
| LNR, Median (Range)                             | 0.33 (0-1)   |
| Distant Metastasis                              |              |
| M0 (%)                                          | 177 (96.2)   |
| M1 (%)                                          | 7 (3.8)      |
| TNM stages                                      |              |
| Early (Stages I, II) (%)                        | 58 (31.5)    |
| Advanced (Stages III, IV) (%)                   | 126 (68.5)   |
| Surgery                                         |              |
| Subtotal resection (%)                          | 159 (86.4)   |
| Non-Subtotal resection (%)                      | 25 (13.6)    |
| Chemotherapy                                    |              |
| No (%)                                          | 35 (19.0)    |
| Yes (%)                                         | 149 (81.0)   |
| Recurrence                                      |              |
| No (%)                                          | 124 (67.4)   |
| Yes (%)                                         | 60 (32.6)    |
| Recurrence location b                           |              |
| Local-regional                                  | 37 (61.7)    |
| Distant                                         | 23 (38.3)    |

*a Others included adenosquamous carcinoma in 3 (1.62%) cases, untypical carcinoid in 1 (0.54%) case, and neuroendocrine carcinoma in 1 (0.54%) case.

*b 60 recurrent cases were evaluated.

### Statistical analysis

Statistical analyses were performed with SPSS software (version 18.0, SPSS Institute, Chicago, IL). The Pearson χ² test or Fisher’s exact test was used to compare qualitative variables. Kaplan-Meier analysis was used for survival analysis and significance among patients’ subgroups was
calculated by log rank test. The Cox regression model was used to perform multivariate analysis. Logistic regression was used to assess the influence of binary factors. Receiver operating characteristic curve (ROC) analysis was used to determine the predictive value of the parameters. Two sided \( P < 0.05 \) was considered as statistically significant.

**Results**

**Major clinico-pathological features and immunohistochemical findings**

Among the 184 cases included in this study were 132 (71.7%) males and 52 (28.3%) females, ranging in age from 25 to 85 yr (Mean ± SD: 57.9 ± 12.9 yr). The main demographic and clinico-pathological characteristics were presented in Table 1.

Immunohistochemistry was performed in all GC TMAs and the result of each specimen was obtained for images-based digital analysis (Figure 1A-1D). MT1-MMP staining was mainly in the cytoplasm or on the cell membrane of tumor cells. Most of the stromal cells were negative, although sporadic positive staining on these cells was also observed (Figure 1E, 1G). CD11b + immunocytes mainly infiltrated into the juncture of cancer nest and stromal (Figure 1F, 1H). The level of MT1-MMP density and CD11b + immunocytes density were presented in Table 1. The 25th percentile of MT1-MMP density was 0.00186 and 138 (75.0%) patients were documented as MT1-MMP positive according to the abovementioned classification criteria. The median value of CD11b + immunocytes were 257 cells per tissue surface unit in square millimeter.

**Relationship between MT1-MMP expression, CD11b + immunocytes density and clinico-pathological features**

There were 77 (55.8%) and 15 (32.6%) patients with high CD11b + immunocytes density in MT1-MMP positive \((n = 138)\) and negative \((n = 46)\) subgroups, respectively \((P = 0.006)\). The likelihood of MT1-MMP expression was
decreased significantly for low CD11b + immunocytes density subgroup (odds ratio (OR) = 0.383 [95%CI: 0.190-0.774], \( P = 0.007 \), Logistic regression). The MT1-MMP expression and CD11b + immunocytes density were correlated with the clinico-pathological features as summarized in Table 2. MT1-MMP expression was correlated with small tumor size (\( P = 0.007 \)), tumor at distal stomach (\( P = 0.027 \)) and increased recurrence risk (\( P = 0.001 \)), but not correlated with age, gender, histological grade, serosa invasion, lymph node status, TNM stage and sites of tumor recurrence (\( P > 0.05 \) for all). CD11b + immunocytes density was correlated with lymph node status (\( P = 0.015 \)), LNR (\( P = 0.018 \)) and TNM stage (\( P = 0.011 \)), but not correlated with age, gender, tumor size, tumor location, histological grade, serosa invasion and recurrence risk (\( P > 0.05 \) for all).

**Table 2 The relationship between MT1-MMP, CD11b + immunocytes density and clinico-pathological features**

| Variables                      | MT1-MMP expression | CD11b + immunocytes density |          |
|--------------------------------|---------------------|-----------------------------|----------|
|                                | Negative (n = 46)   | Positive (n = 138)          |          |
|                                | N (%)               | N (%)                       | P        |
| Age (yrs)                      |                     |                             |          |
| <60                            | 26 (56.5)           | 20 (43.5)                   | 0.669    |
| ≥60                            | 73 (52.9)           | 65 (47.1)                   |          |
| Gender                         | Male                | 33 (25.0)                   | 99 (75.0)| 1.000    |
|                               | Female              | 13 (25.0)                   | 39 (75.0)|          |
| Tumor size (cm²) a             |                     |                             |          |
| <16                            | 12 (16.4)           | 61 (83.6)                   | 0.007    |
| ≥16                            | 31 (35.2)           | 57 (64.8)                   |          |
| Location                       | Distal              | 18 (18.4)                   | 80 (81.6)| 0.027    |
|                               | Non-distal          | 28 (32.6)                   | 58 (67.4)|          |
| Histological grade b           | 1/2                 | 13 (23.6)                   | 42 (76.4)| 0.845    |
|                               | 3/4                 | 31 (25.0)                   | 93 (75.0)|          |
| Lymph node metastasis          | Yes                 | 31 (23.7)                   | 100 (76.3)| 0.511    |
|                               | No                  | 15 (28.3)                   | 38 (71.7)|          |
| LNR c                          | ≤0.33               | 27 (28.7)                   | 67 (71.3)| 0.233    |
|                               | >0.33               | 19 (21.1)                   | 71 (78.9)|          |
| Serosa invasion (T stage)      | T1-2                | 4 (14.8)                    | 23 (85.2)| 0.186    |
|                               | T3-4                | 42 (26.8)                   | 115 (73.2)|          |
| TNM staging                    | Early (I, II)       | 13 (22.4)                   | 45 (77.6)| 0.583    |
|                               | Advanced (III, IV)  | 33 (26.2)                   | 93 (73.8)|          |
| Recurrence                     | Yes                 | 9 (15.0)                    | 51 (85.0)| 0.029    |
|                               | No                  | 37 (29.8)                   | 87 (70.2)|          |
| Recurrence location d          | Local-regional      | 7 (18.9)                    | 30 (81.1)| 0.460    |
|                               | Distant             | 2 (8.7)                     | 21 (91.3)|          |

\( ^{a} \) Analysis was performed based on 161 patients with complete data of tumor size (TS).\( ^{b} \) Analysis was performed based on 179 patients with gastric adenocarcinoma.\( ^{c} \) The median of lymph node ratio (LNR) was 0.33 (6 cases), and GC cases were different in distinct subgroups.\( ^{d} \) 60 recurrent cases were included.
Survival analysis

For 184 cases, the median OS was 26.8 (range 0.8-102.3) months, and the 1-, 3-, and 5-yr survival rate was 79.3%, 50.5% and 37.4%, respectively (Figure 2A). As expected, those traditional factors were associated with GC patients’ OS, such as tumor size, histological grade, lymph node status, serosa invasion and TNM stage ($P < 0.05$ for all). In addition, both high CD11b+ immunocytes density and MT1-MMP negative expression were correlated with better OS ($P$ value was 0.031 and 0.015, respectively) (Figure 2B, 2C). The discrimination ability in OS was increased in LNR subgroups ($P < 0.001$) compared to lymph nodes status subgroups ($P = 0.015$) (Figure 2D, 2E), and ROC analysis showed that, in terms of predicting risk of death, the classification by LNR (Area under the curve: 0.659 [95%CI: 0.579-0.739], $P < 0.001$) had better performance than positive lymph nodes number (Areas under the curve: 0.568 [95%CI: 0.484-0.653], $P = 0.114$). All results indicated that MT1-MMP positive, low CD11b+ immunocytes density and high LNR were risk factors related to poor prognosis (Figure 2, Table 3).

Figure 2 Cumulative OS of GC patients. (A) OS of 184 GC patients. (B) Low CD11b+ immunocytes density was related to poor OS. (C) Patients in MT1-MMP positive group were at higher risk for death. (D, E) Both lymph nodes status and LNR were correlated with poor OS, but LNR could better differentiate patient subgroups. (F) Combined Features could indicate OS of GC patients more accurately.
| Variables                              | N     | N of death (%) | Median OS (Range) | 5-year survival rate (%) | Log-rank test $\chi^2$ value | P     |
|----------------------------------------|-------|----------------|-------------------|--------------------------|-------------------------------|-------|
| Age (yrs)                              |       |                |                   |                          |                               |       |
| <60                                    | 99    | 52 (52.5)      | 30.1 (1.5-99.5)   | 45.1                     | 3.584                         | 0.058 |
| ≥60                                    | 85    | 56 (65.9)      | 24.8 (0.8-102.3)  | 28.6                     |                               |       |
| Gender                                 |       |                |                   |                          |                               |       |
| Male                                   | 132   | 74 (56.1)      | 30.3 (0.8-102.3)  | 40.0                     | 2.114                         | 0.146 |
| Female                                 | 52    | 34 (65.4)      | 25.1 (1.3-94.8)   | 30.3                     |                               |       |
| Tumor size (cm$^2$) $^a$               |       |                |                   |                          |                               |       |
| <16                                    | 73    | 35 (47.9)      | 41.6 (1.1-99.5)   | 52.9                     | 7.882                         | 0.005 |
| ≥16                                    | 88    | 57 (64.8)      | 24.2 (0.8-102.3)  | 29.2                     |                               |       |
| Histological grade $^b$                |       |                |                   |                          |                               |       |
| 1/2                                    | 55    | 88 (56.1)      | 30.1 (1.1-102.3)  | 54.2                     | 13.412                        | <0.001|
| 3/4                                    | 124   | 20 (74.1)      | 16.8 (0.8-74.9)   | 30.1                     |                               |       |
| Lymph nodes metastasis                 |       |                |                   |                          |                               |       |
| Yes                                    | 131   | 83 (63.4)      | 24.8 (0.8-102.3)  | 52.9                     | 5.895                         | 0.015 |
| No                                     | 53    | 25 (47.2)      | 34.1 (6.1-99.5)   | 30.5                     |                               |       |
| Serosa invasion (T stage)              |       |                |                   |                          |                               |       |
| T1-2                                   | 27    | 7 (25.9)       | 58.9 (20.2-99.5)  | 74.9                     | 14.742                        | <0.001|
| T3-4                                   | 157   | 101 (64.3)     | 24.8 (0.8-102.3)  | 30.8                     |                               |       |
| TNM                                    |       |                |                   |                          |                               |       |
| Early (I, II)                          | 58    | 26 (44.8)      | 35.8 (6.1-99.5)   | 54.0                     | 9.823                         | 0.002 |
| Advanced (III, IV)                    | 126   | 82 (65.1)      | 22.8 (0.8-102.3)  | 29.2                     |                               |       |
| Surgery                                |       |                |                   |                          |                               |       |
| SR                                     | 159   | 89 (56.0)      | 30.0 (0.8-102.3)  | 39.8                     | 5.902                         | 0.015 |
| TR/CR                                  | 25    | 19 (76.0)      | 18.0 (3.8-89.9)   | 21.8                     |                               |       |
| Chemotherapy                           |       |                |                   |                          |                               |       |
| Yes                                    | 149   | 87 (49.7)      | 33.5 (5.3-99.5)   | 35.9                     | 0.016                         | 0.900 |
| No                                     | 35    | 21 (60.0)      | 28.4 (0.8-102.3)  | 40.0                     |                               |       |
| LNR $^c$                               |       |                |                   |                          |                               |       |
| ≤0.33                                  | 94    | 41 (43.6)      | 38.8 (1.1-102.3)  | 55.1                     | 24.881                        | <0.001|
| >0.33                                  | 90    | 67 (74.4)      | 20.1 (0.8-99.1)   | 18.3                     |                               |       |
| MT1-MMP                                |       |                |                   |                          |                               |       |
| Negative                               | 46    | 18 (39.1)      | 35.7 (3.8-79.3)   | 54.0                     | 5.869                         | 0.015 |
| Positive                               | 138   | 90 (65.2)      | 25.4 (0.8-102.3)  | 32.2                     |                               |       |
| CD11b + immunocytes density            |       |                |                   |                          |                               |       |
| Low                                    | 92    | 62 (67.4)      | 25.1 (0.8-99.1)   | 27.6                     | 4.655                         | 0.031 |
| High                                   | 92    | 46 (50.0)      | 30.7 (1.3-102.3)  | 46.7                     |                               |       |
| Combined features (MT1-MMP density, CD11b + immunocytes density and LNR) |       |                |                   |                          |                               |       |
| Group I                                | 73    | 26 (35.6)      | 38.7 (6.1-94.1)   | 61.4                     | 28.173                        | <0.001|
| Group II                               | 111   | 82 (73.9)      | 18.1 (0.8-90.9)   | 21.1                     |                               |       |

$^a$ Analysis was performed based on 161 patients with complete data of tumor size. $^b$ Analysis was performed based on 179 patients with gastric adenocarcinoma. $^c$ The median of LNR was 0.33 (6 cases), and GC cases were different in distinct subgroups. OS: overall survival; SR: subtotal resection; TR: total resection; CR: combined resection; LNR: lymph node ratio.
As we proposed above, combined features based on the number of risk factors were explored to improve prediction of GC prognosis (Table 3). Thus, patients were divided into two subgroups according to the number of risk features: group I, less than two risk factors were observed; and group II, two or three risk factors were observed. Combined analysis showed that the OS of patients in group II was significantly shorter than patients in group I ($P < 0.001$) (Figure 2F).

**Multivariate analysis and ROC analysis**

In univariate analysis, traditional clinico-pathological features (such as tumor size, T stage, TNM stage, surgery methods, and recurrence status), MT1-MMP expression, CD11b + immunocytes density and LNR were associated with OS. Furthermore, the death risk in combined group II increased significantly ($P < 0.001$).

Factors showing significance by univariate analysis were integrated into multivariate Cox proportional hazards analysis. In this study, LNR, MT1-MMP, CD11b and combined features were highly correlated. Therefore, two separate multivariate models were generated to avoid the multicollinearity among those variables. LNR, MT1-MMP expression and CD11b + immunocytes density were independent prognostic factors for OS after excluding other confounding factors ($P < 0.05$ for all). Moreover, the combined features were independent prognostic factor, too ($HR = 3.818 \ [95\% CI: 2.223-6.557], P < 0.001$) (Table 4).

ROC analysis was implemented to further evaluate the prognostic performance of the four independent factors in this study. Combined features would be better to predict the clinical outcomes of GC patients compared to other factors (Area under the curve: 0.689 [95% CI: 0.609-0.768], $P < 0.001$) (Figure 3).

![Figure 3](http://www.translational-medicine.com/content/11/1/153)

**Figure 3** ROC analysis of the predictive value for death. Among the 4 independent prognostic factors, the area under the curve of the new combined feature was the largest one. The combined feature could have better prognostic performance in GC patients.
**Discussion**

We have proposed a combined analysis of integrated tumor stromal features as a useful strategy to evaluate cancer progression and patient survival in GC based on our studies focused on the co-evolution of tumor cells and tumor microenvironment and [19,21,22]. This study was designed to explore the feasibility of this combined strategy. In addition, an improved automation method to analyze the digitalized images was used to ensure both reproducibility and good performance in this study. As Fridman [23] suggested, such methods would pave the way to better understanding the complex tumor microenvironment, as well as to the routine evaluation of parameters for clinical management of cancer patients. Herein, 184 GC cases were included to evaluate the prognostic values of optimized conventional pathological prognostic factors, cellular molecular factors, immune factors and the combined features. This is the essential step towards establishing a workable prognostic system integrating both clinico-pathological, tumor and stromal features in our series studies [19,21,22].

Of 184 cases, the demographics and clinico-pathological characteristics are similar to those reported in other large series of GC population [24]. Our results showed that the expression of MT1-MMP was frequently correlated with increased recurrence risk, but the difference in relapse location was not statistically significant. These results were similar to previous report [25]. MT1-MMP plays important role in degrading types I and IV collagens to facilitate cancer cells spreading. In addition, MT1-MMP can promote angiogenesis and micrometastasis via vascular route [26].

With regard to immune cells, the nature, density and location are important parameters to comprehensively evaluate the in situ immune reaction and the specific role in cancer progression. In this study, CD11b + immunocytes were mostly located at the invasive front. The difference in CD11b + immunocytes density was statistically significant between lymph nodes metastasis and non-metastasis subgroups. Furthermore, the CD11b + immunocytes density was higher in early than advanced GC patients, similar to the reports by Sconocchia et al. and Ladoire et al. [27,28]. Hence, we hypothesized that CD11b + immunocytes could prevent the lymph nodes metastasis by active immunosurveillance process.

The prognostic value of traditional clinico-pathological prognostic factors has been validated [29,30]. Interestingly, some studies reported that the LNR was a better predictor of patient outcome than lymph nodes status only. LNR may be an alternative stratification in cases where few nodes are retrieved [3,8]. LNR has also been adopted by the Japanese Gastric Cancer Association (JGCA) [31].

Researches focused on molecular factors for cancer prognosis have attracted increasing attention [32,33]. In this study, MT1-MMP expression and CD11b + immunocytes density were independent prognostic factors, which partly validated others’ conclusions about MT1-MMP and CD11b + immunocytes. Kanazawa et al. [34] reported that MT1-MMP expression could be considered as a useful independent predictor of outcomes in colorectal cancer patients. The results presented by Mahmoud et al. [35] confirmed the presence of efficient immunologic antitumor defense mechanisms in human breast cancer. It is proposed that immune score would identify a population of patients who would derive substantial benefit from further stimulating their immune response [36]. Several studies have also provided evidence of immune criteria to predict which tumors have a high risk of death [35,37].

Given the fact that tumor biology is often dictated by several essential cellular and microenvironmental alterations, it may be naive to think that single factor would be enough as prognostic factors in cancer [38]. Solutions are now being explored by analyzing multiple factors with tissue microarrays, which has been emerged as an essential tool in the discovery and validation of tissue biomarkers [39]. To our knowledge, combined analysis is a promising method to translate experimental results into clinical application [40]. Based on our results and current knowledge in cancer progression, we proposed a new prognostic model that combines pathological, cellular and molecular features. This study showed that the combined features were independent prognostic factors for OS. The death risk of GC patients in group II was increased by 200% and this combined features would better predict GC patients’ outcomes.

The development of tumor biomarkers ready for clinical use is complex, and a useful prognostic marker must be a proven independent, significant factor, that is easy to determine and interpret and has therapeutic impact [41]. Although the combined features described herein could address these conditions, the promising results are based on retrospective analysis, which is the limitation of this study. Prospective randomized clinical trials to evaluate the clinical utility of a prognostic or predictive biomarker are the gold standard, but such trials are costly and difficult to implement, and more efficient indirect “retrospective analysis” using archived specimens would be an alternative method for a long time [42].

**Conclusions**

Our study provides evidence for the value of the combined features to predict OS in GC patients. The combined features of positive MT1-MMP, low CD11b + immunocytes density and high LNR may be used as useful prognostic factor in clinical circumstance in future. Further studies with larger sample size could help gain deeper insights into the role of combined features.
Competing interests
The authors declare that they have no competing interests.

Authors' contributions
PCW selects the research topic, conducts the pathological examination, statistical analysis and writes manuscript. WLW, FM and YGF conduct the pathological examination. LY and PDW conceive the study project, organizes the whole study process, provides financial support, and finalizes the manuscript. All authors have read and approved the final manuscript.

Acknowledgement
This work was supported by Academic Award for Excellent Ph.D. Candidates Funded by Ministry of Education of China (No. 5052110303104), Science Fund of the National Natural Science Foundation of China (No. 81171396), Science Fund for Creative Research Groups of the National Natural Science Foundation of China (No. 20621502, 20921062), and the Fundamental Research Funds for the Central Universities of Ministry of Education of China (No. 4103005).

Author details
1Department of Oncology, Zhongnan Hospital of Wuhan University, No. 169 Donghu Road, Wuchang District Wuhan 430071, People's Republic of China.
2Hubei Key Laboratory of Tumor Biological Behaviors & Hubei Cancer Clinical Study Center, Zhongnan Hospital of Wuhan University, No. 169 Donghu Road, Wuchang District Wuhan 430071, People's Republic of China.
3Department of Pathology, Zhongnan Hospital of Wuhan University, No. 169 Donghu Road, Wuchang District Wuhan 430071, People's Republic of China.
4Key Laboratory of Analytical Chemistry for Biology and Medicine (Ministry of Education), College of Chemistry and Molecular Sciences, and State Key Laboratory of Virology, Wuhan University, Wuhan 430072, People's Republic of China.

Received: 29 January 2013 Accepted: 13 June 2013
Published: 20 June 2013

References
1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D: Global Cancer Statistics. CA-Cancer J Clin 2011, 61:69–90.
2. Mlecnik B, Tosolini M, Kirkovsky A, Berger A, Blinda G, Meatchi T, Bruneval P, Trajanszki Z, Frindel WH, Pages F, Galon J: Histopathologic-based prognostic factors of colorectal cancers are associated with the state of the local immune reaction. J Clin Oncol 2011, 29:610–618.
3. Waneke VS, Behrens HM, Hartmann JT, Held H, Becker T, Schwarz NT, Rocken C: Cohort Study Based on the Seventh Edition of the TNM Classification for Gastric Cancer: Proposal of a New Staging System. J Clin Oncol 2011, 29:2364–2371.
4. Wong H, Yau T: Targeted Therapy in the Management of Advanced Gastric Cancer: Are We Making Progress in the Era of Personalized Medicine? Oncologist 2012, 17:346–358.
5. Hemingway H: Ten steps towards improving prognosis research. Brit Med J 2009, 339:b4184.
6. Maduekwe UN, Lauwers GY, Fernandez-Del-Castillo C, Berger DL, Ferguson CM, Rattraw DW, Yoon SS: New metastatic lymph node ratio system reduces stage migration in patients undergoing D1 lymphadenectomy for gastric adenocarcinoma. Ann Surg Oncol 2010, 17:1267–1277.
7. Xu DZ, Geng QR, Long ZI, Zhan YQ, Li W, Zhou ZW, Chen YB, Sun XW, Chen G, Liu Q: Positive lymph node ratio is an independent prognostic factor in gastric cancer after D2 resection regardless of the examined number of lymph nodes. Ann Surg Oncol 2009, 16:319–326.
8. Wang W, Xu DZ, Li YF, Guan YX, Sun XW, Chen YB, Kesarji R, Huang CY, Li W, Zhan YQ, Zhou ZW: Tumor-ratio-metastasis staging system as an alternative to the 7th edition UICC TNM system in gastric cancer after D2 resection—results of a single-institution study of 1343 Chinese patients. Ann Oncol 2011, 22:409–410.
9. Hanahan D, Weinberg RA: Hallmarks of cancer: the next generation. Cell 2011, 144:646–674.
10. Joyce JA, Pollard JW: Microenvironmental regulation of metastasis. Nat Rev Cancer 2009, 9:239–252.
11. Pintouclou R, Lizarraga F, Chavrier P: Matrix invasion by tumour cells: a focus on MT1-MMP trafficking to invadopodia. J Cell Sci 2009, 122:3015–3024.
12. Below L, Zhou J, Christopherson RI: Cell Surface Markers in Colorectal Cancer Prognosis. Int J Mol Sci 2011, 12:78–113.
13. Ota I, Liu XY, Hu YX, Weiss SI: Induction of a MT1-MMP and MT2-MMP-dependent basement membrane transmigration program in cancer cells by Snafil. PROC NAT ACADEM SCI USA 2009, 106:20318–20323.
14. Galon J, Costes A, Sanchez-Cabo F, Kirkovksy A, Mlecnik B, Lagorce-Pages C, Tosolini M, Carus M, Berger A, Wind P, et al: Typing, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science, 313:1960–1964.
15. Stepanova K, Sinkora M: The expression of CD25, CD11b, SWC1, SWC7, MHC-II, and family of CD45 molecules can be used to characterize different stages of gamma delta T lymphocytes in pigs. Develop Comp Immunol 2012, 36:278–290.
16. Lundahl J, Jacobson SH, Paulsson JM: IL-8 from Local Subcutaneous Wounds Regulates CD11b Activation. Scand J Immunol 2012, 75:419–425.
17. Blankenstein T, Coulie PG, Gilboa E, Jaffe EM: The determinants of tumour immunogenicity. Nat Rev Cancer 2012, 12:307–313.
18. Wittelk C, Meyer H-J: TNM Classification of Malignant Tumors (ed 7). Germany: Wiley; 2010.
19. Peng CW, Liu XL, Liu X, Yu Y: Co-evolution of cancer microenvironment reveals distinctive patterns of gastric cancer invasion: laboratory evidence and clinical significance. J Transl Med 2010, 8:101.
20. Marchet A, Mocellin S, Ambrosi A, Morgagni P, Garcea D, Marrelli D, Roviello F, De Manzoni G, Minicacci A, Natalini G, et al: The ratio between metastatic and examined lymph nodes (N ratio) is an independent prognostic factor in gastric cancer regardless of the type of lymphadenectomy: results from an Italian multicentric study in 1853 patients. Ann Surg 2007, 245:543–552.
21. Peng CW, Tian Q, Yang GF, Fang M, Zhang ZL, Peng J, Pang DW, Li Y: Quantum-dots based simultaneous detection of multiple biomarkers of tumor stromal features to predict clinical outcomes in gastric cancer. Biomaterials 2012, 33:5427–5432.
22. Peng CW, Liu XL, Chen C, Liu Y, Yang X-Q, Pang D-W, Zhu X-B, Li Y: Patterns of cancer invasion revealed by QDs-based quantitative multiplexed imaging of tumor microenvironment. Biomaterials 2011, 32:2907–2917.
23. Fridman WH, Galon J, Pages F, Tartou E, Sauers-Fridman C, Kroemer G: Prognostic and Predictive Impact of Intra- and Peritumoral Immune Infiltrates. Cancer Res 2011, 71:5601–5605.
24. Leung WK, Wu MS, Kuagawa Y, Kim JJ, Yeoh KG, Goh KL, Wu KC, Wu DC, Sollano J, Kachintorn U, et al: Screening for gastric cancer in Asia: current evidence and practice. Lancet Oncol 2008, 9:279–287.
25. Zhang M, Zhu GY, Gao HY, Zhao SP, Xue YW: Expression of Tissue Levels of Matrix Metalloproteinases and Tissue Inhibitors of Metalloproteinases in Gastric Adenocarcinoma. J Surg Oncol 2011, 103:281–291.
26. Perentes JY, Kirkpatrick ND, Nagono S, Smith EY, Shaver CM, Sgroi D, Garkavtsev I, Munn LL, Jain RK, Boucher Y: Cancer Cell-Associated MT1-MMP Promotes Blood Vessel Invasion and Distant Metastasis in Triple-Negative Mammary Tumors. Cancer Res 2011, 71:4527–4538.
27. Sconocchia G, Zobec I, Lugli A, Calabrese D, Izzo G, Karamitopoulou E, Patosuirs ES, Peros G, Horic M, Tornillo L, et al: Tumor infiltration by FC gamma RII (CD16) + myeloid cells is associated with improved survival in patients with colorectal cancer. Int J Cancer 2011, 128:2663–2672.
28. Ladoire S, Mignot G, Dabakuyo S, Aroul S, Apetoh L, Rebe C, Coudert B, Martin F, Bizollon MH, Vanoli A, et al: In situ immune response after neoadjuvant chemotherapy for breast cancer predicts survival. J Pathol 2011, 224:389–400.
29. Raucci S, Dioni G, Boni L, Rovera F, Dioni R: How does the 7th TNM edition fit in gastric cancer management? Ann Surg Oncol 2011, 18:1219–1221.
30. Songun I, Putter H, Kranenbarg EM, Waksao M, Van de Velde CJH: Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch D1D2 trial. Lancet Oncol 2010, 11:439–449.
31. Association JGC: Japanese classification of gastric carcinoma: 3rd English edition. Gastric Cancer 2011, 14:101–112.
32. Jung H, Lee HH, Song KY, Jeon HM, Park SH: Validation of the seventh edition of the american joint committee on cancer TNM staging system for gastric cancer. Cancer 2011, 117:2371–2378.
33. Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Oomura Y, Satoh T, et al: Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA):

Peng et al. Journal of Translational Medicine 2013, 11:153
http://www.translational-medicine.com/content/11/1/153
Page 10 of 11
a phase 3, open-label, randomised controlled trial. *Lancet* 2010, 376:687–697.

34. Kanazawa A, Oshima T, Yoshihara K, Tamura S, Yamada T, Inagaki D, Sato T, Yamamoto N, Shiozawa M, Morinaga S, et al. Relation of MT1-MMP Gene Expression to Outcomes in Colorectal Cancer. *J Surg Oncol* 2010, 102:571–575.

35. Mahmoud SM, Paish EC, Powe DG, Macmillan RD, Grainge MJ, Lee AH, Ellis IO. Green AR. Tumor-infiltrating CD8+ lymphocytes predict clinical outcome in breast cancer. *J Clin Oncol* 2011, 29:1949–1955.

36. Brousard EK, Disis ML. TNM staging in colorectal cancer: T is for T cell and M is for memory. *J Clin Oncol* 2011, 29:601–603.

37. Mahmoud SMA, Paish EC, Powe DG, Macmillan RD, Lee AH, Ellis IO, Green AR. An evaluation of the clinical significance of FOXP3(+) infiltrating cells in human breast cancer. *Breast Cancer Res Treat* 2011, 127:99–108.

38. Oldenhuis C, Oosting SJ, Gietema JA, De Vries EG. Prognostic versus predictive value of biomarkers in oncology. *Eur J Cancer* 2008, 44:946–953.

39. Hewitt SM. Tissue Microarrays as a Tool in the Discovery and Validation of Predictive Biomarkers. *Molecular Profiling: Methods and Protocols* 2012, 823:201–214.

40. Solis LM, Behrens C, Raso MG, Lin HY, Kadara H, Yuan P, Galindo H, Tang X, Lee JJ, Kalhor N, et al. Histologic patterns and molecular characteristics of lung adenocarcinoma associated with clinical outcome. *Cancer* 2012, 118:2889–2899.

41. Pages F, Kirilovsky A, Milenkiv B, Asslabor M, Tosolini M, Bindea G, Lagorce C, Wind P, Marigo F, Bruneval P, et al. In situ cytotoxic and memory T cells predict outcome in patients with early-stage colorectal cancer. *J Clin Oncol* 2009, 27:5944–5951.

42. Simon RM, Paki S, Hayes DF. Use of Archived Specimens in Evaluation of Prognostic and Predictive Biomarkers. *J Natl Cancer Inst* 2009, 101:1446–1452.

Cite this article as: Peng et al. Combined features based on MT1-MMP expression, CD11b+ immunocytes density and LNR predict clinical outcomes of gastric cancer. *Journal of Translational Medicine* 2013 11:153.